Publications & News

WilmerHale Counsels Investors Abingworth Bioventures and Atlas Venture in IFM Therapeutics Acquisition by Bristol-Myers Squibb

August 14, 2017

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders. IFM is a privately held biopharmaceutical company based in Boston, Massachusetts, and financed by Abingworth Bioventures and Atlas Venture.

The WilmerHale deal team representing Atlas Venture and Abingworth Bioventures included Stuart Falber, Bill Caporizzo, Steve Barrett and Jeff Hermanson.

Read IFM's press release for more information.